Literature DB >> 33245409

Exacerbated hemodynamic response during exercise in cancer patients prior to autologous hematopoietic stem cell transplantation.

Ana Luiza Machado Dias1, Mateus Camaroti Laterza1, Pedro Augusto de Carvalho Mira1,2, Isabelle Magalhães Guedes Freitas3, Patrícia Fernandes Trevizan1, Daniel Godoy Martinez1, Leonardo Barbosa de Almeida4.   

Abstract

PURPOSE: Chemotherapy treatment can lead to cardiovascular toxicity and physical impairment prior to autologous hematopoietic stem cell transplantation (auto-HSCT). Cardiovascular adjustments during exercise and the exercise capacity remain unknown in patients prior to auto-HSCT. Thus, the hemodynamic responses during exercise and exercise capacity were evaluated using a novel effort test in patients prior to auto-HSCT.
METHODS: Thirty patients prior to auto-HSCT (BMT group: 44.6 ± 14.1 years) and 23 control participants (CON group: 43.9 ± 16.6 years) performed the 6-Minute Step Test (6MST) to assess their exercise capacity and the hemodynamic responses during exercise. Systolic and diastolic blood pressure (SBP and DBP), heart rate (HR), and oxygen saturation (SpO2) were measured during the test. Rate-pressure product (RPP) was calculated multiplying SBP by HR. The highest HR value recorded during the test was compared with the maximum HR predicted by age and was used as % of maximum HR (%HRmax).
RESULTS: The number of steps up and down performed by the BMT group was lower than CON (108.8 ± 25.3 vs. 127.5 ± 34.4 steps, P = 0.02). The BMT group showed a higher magnitude of increase in SBP and RPP during the 6MST when compared to CON (ΔSBP: 18.5 ± 11.45 vs. 8.30 ± 18.46 mmHg, P = 0.01; and ΔRPP: 8197.3 ± 3829.1 vs. 6170.9 ± 3568.9 mmHg beats min-1, P = 0.05). The BMT group exhibited higher SpO2 and HR values throughout the protocol (P < 0.05), reaching a higher %HRmax than CON group (76.9 ± 9.6 vs. 66.4 ± 8.9%, P < 0.01).
CONCLUSIONS: Patients with indication for auto-HSCT have exacerbated chronotropic and pressor responses during exercise and reduced exercise capacity in the 6MST.

Entities:  

Keywords:  Cardiotoxicity; Exercise tolerance; Hematopoietic stem cell transplantation; Physical functional performance

Year:  2020        PMID: 33245409     DOI: 10.1007/s00520-020-05911-1

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  21 in total

Review 1.  A Review of Autologous Stem Cell Transplantation in Lymphoma.

Authors:  Umar Zahid; Faisal Akbar; Akshay Amaraneni; Muhammad Husnain; Onyee Chan; Irbaz Bin Riaz; Ali McBride; Ahmad Iftikhar; Faiz Anwer
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

2.  Cardiac output response to exercise in patients before allogenic hematopoietic stem cell transplantation.

Authors:  Shinya Yoshida; Fujiko Someya; Tetsutaro Yahata
Journal:  Int J Clin Oncol       Date:  2018-07-05       Impact factor: 3.402

3.  Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease.

Authors:  Saro H Armenian; Can-Lan Sun; Tabitha Vase; Kirsten K Ness; Emily Blum; Liton Francisco; Kalyanasundaram Venkataraman; Raynald Samoa; F Lennie Wong; Stephen J Forman; Smita Bhatia
Journal:  Blood       Date:  2012-10-03       Impact factor: 22.113

4.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

5.  Cardiopulmonary exercise testing prior to myeloablative allo-SCT: a feasibility study.

Authors:  C R Kelsey; J M Scott; A Lane; E Schwitzer; M J West; S Thomas; J E Herndon; M G Michalski; M E Horwitz; T Hennig; L W Jones
Journal:  Bone Marrow Transplant       Date:  2014-07-28       Impact factor: 5.483

6.  Impaired physiological function and health-related QOL in patients before hematopoietic stem-cell transplantation.

Authors:  Shinichiro Morishita; Katsuji Kaida; Kazuhiro Ikegame; Satoshi Yoshihara; Kyoko Taniguchi; Masaya Okada; Norihiko Kodama; Hiroyasu Ogawa; Kazuhisa Domen
Journal:  Support Care Cancer       Date:  2011-04-09       Impact factor: 3.603

Review 7.  Hematologic Malignancies: Plasma Cell Disorders.

Authors:  Madhav V Dhodapkar; Ivan Borrello; Adam D Cohen; Edward A Stadtmauer
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 8.  Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic training.

Authors:  Jessica M Scott; Saro Armenian; Sergio Giralt; Javid Moslehi; Thomas Wang; Lee W Jones
Journal:  Crit Rev Oncol Hematol       Date:  2015-11-17       Impact factor: 6.312

9.  Prognostic Importance of Pretransplant Functional Capacity After Allogeneic Hematopoietic Cell Transplantation.

Authors:  Lee W Jones; Sean M Devlin; Molly A Maloy; William A Wood; Sharlynn Tuohy; Noel Espiritu; Jennifer Aquino; Tiffany Kendig; Meghan G Michalski; Boglarka Gyurkocza; Wendy L Schaffer; Benzar Ali; Sergio Giralt; Ann A Jakubowski
Journal:  Oncologist       Date:  2015-10-07

10.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).

Authors:  Jose Luis Zamorano; Patrizio Lancellotti; Daniel Rodriguez Muñoz; Victor Aboyans; Riccardo Asteggiano; Maurizio Galderisi; Gilbert Habib; Daniel J Lenihan; Gregory Y H Lip; Alexander R Lyon; Teresa Lopez Fernandez; Dania Mohty; Massimo F Piepoli; Juan Tamargo; Adam Torbicki; Thomas M Suter
Journal:  Eur Heart J       Date:  2016-08-26       Impact factor: 29.983

View more
  1 in total

1.  Inspiratory muscle training in addition to conventional physical rehabilitation in hospitalized patients undergoing hematopoietic stem cell transplantation: a randomized controlled trial.

Authors:  Leonardo Barbosa Almeida; Mateus Camaroti Laterza; Maria Urbana Pinto Brandão Rondon; Luciana Diniz Nagem Janot de Matos; Catherine L Granger; Linda Denehy; Cristino Carneiro Oliveira; Patricia Fernandes Trevizan; Daniel Godoy Martinez
Journal:  Support Care Cancer       Date:  2022-09-29       Impact factor: 3.359

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.